Lexence advised uPATCH in connection with the investment by INZET in uPATCH.

Lexence advised uPATCH on its Seed Investment by INZET, a fund managed by Shaping Impact Group. This investment enables uPATCH to accelerate its mission of making drug delivery accessible to everyone globally through innovative microneedle technology.

uPATCH is a health-tech startup developing applicators for microneedle array patches. This technology, recognised by the World Health Organisation (WHO) as the next generation of drug delivery, offers numerous advantages, such as painless administration, reduced use of active pharmaceutical ingredients, and the elimination of reliance on refrigerated distribution. With this investment, uPATCH can expand its R&D capabilities, implement an ISO13485 quality management system, and establish new partnerships to create global impact.

Shaping Impact Group is an impact-first Venture Capital fund focused on investments in social enterprises that improve daily care for individuals or contribute to the prevention of chronic health conditions. The fund supports innovative projects prioritising societal impact and collaborates with entrepreneurs to deliver sustainable solutions.

The team of Lexence consisted of: Iris Hoekstra and Maxime Loos